Table 2. Studies Reflecting Cisplatin-Associated Hearing Loss in Adults.
| Study | Country | Type of study | Audiological tests conducted | Patient population | No. of patients who developed ototoxicity |
|---|---|---|---|---|---|
| Malgonde et al 36 | India | Prospective | Pure tone audiometry (frequencies not specified) and short increment sensitivity index test | 34 patients with head and neck cancers receiving cisplatin-containing chemotherapy and concomitant radiation therapy | 34 (100%) |
| Whitehorn et al 37 | South Africa | Retrospective cross sectional | Air (0.25–8 kHz) and bone conduction pure tone audiometry | 107 patients receiving cisplatin-containing chemotherapy, irrespective of the type of the cancer | 59 (55.1%) |
| Nitz et al 38 | Germany | Prospective longitudinal trinational population based | Air (0.125–8 kHz) and bone conduction pure tone audiometry | 1 patient with soft-tissue sarcoma and 16 with osteosarcoma, receiving cisplatin- and/or carboplatin-containing chemotherapy | 6 (35.3%) |
| Arora et al 5 | India | Prospective, randomized, and observational | Pure tone air (0.25–16 kHz) and bone conduction audiometry Results are reflective of frequencies 4–16 kHz |
57 patients receiving cisplatin-containing chemotherapy: 10 patients (low-dose group—carcinoma of the larynx) 35 patients (middle-dose group—head and neck cancers, carcinoma of the cervix) 12 patients (high-dose group—carcinoma of the lung and carcinoma of the testis |
- 6 (60%) 35 (100%) 12 (100%) |
| Dell'Aringa et al 39 | Brazil | Case series | Tympanometry, acoustic reflex threshold testing, DPOAEs, air (0.25–8 kHz) and bone conduction pure tone audiometry, speech audiometry | 17 patients with extracranial head and neck cancers receiving cisplatin-containing chemotherapy and concomitant radiation therapy | 12 left ears (70.5%), 11 right ears (64.7%) |
| Schultz et al 40 | Brazil | Prospective | Full audiometric evaluations, with only air (0.25–8 kHz) and bone conduction pure tone audiometry thresholds computed | 31 patients receiving cisplatin-containing chemotherapy, irrespective of the type of cancer | NCI 12 criteria—12 (38%), Brock et al's criterion—19 (65%), ASHA criteria—17 (54%), David and Silverman's criteria—9 (29%) |
| Zuur et al 41 | The Netherlands | Prospective | Air (0.125–16 kHz) and bone conduction pure tone audiometry | 60 patients with locally advanced head and neck cancer, receiving cisplatin-containing chemotherapy and concomitant radiation therapy | Up to 8 kHz—19 (31%) Up to 16 kHz—28 (47%) |
| Dutta et al 27 | India | Prospective | Pure tone audiometry (frequencies not specified) | 60 patients receiving cisplatin-containing chemotherapy—type of cancer not indicated 51—low-dose group 9—high-dose group |
9 (15%) 6 (12%) 3 (33%) |
| Strumberg et al 42 | Germany | Retrospective | Pure tone air (0.125–12 kHz) and bone conduction audiometry, TEOAE test | 32 patients with testicular cancer receiving cisplatin-containing chemotherapy | 21 (70%) |
| Nagy et al 43 | USA | Retrospective | Tympanometry, air (0.25–8 kHz) conduction pure tone audiometry | 53 patients with oesophageal, lung, or head and neck cancer receiving cisplatin-containing chemotherapy and concomitant radiation therapy (only for head and neck cancer) | 19 (36%) |
| Bokemeyer et al 26 | Germany | Retrospective | Pure tone air (0.5–8 kHz) and bone audiometry | 86 patients with testicular cancer receiving cisplatin-containing chemotherapy | 57 (66%) |
| Waters et al 44 | Canada | Retrospective | Pure tone air (0.25–8 kHz) and bone conduction audiometry, immittance audiometry, and speech audiometry | 60 patients with advanced ovarian carcinomas receiving cisplatin-containing chemotherapy 39—low-dose, short treatment (25 from LDE group and 14 new cases after treatment modification) 8—low-dose, blocks 25—low-dose, extended treatment 13—high-dose, short treatment |
6 (15%) 0 (0%) 9 (36%) 12 (92%) |
Abbreviations: ASHA, American Speech Language Hearing Association; DPOAEs, distortion product otoacoustic emissions; LDE, low dose extended treatment; TEOAE, transient evoked otoacoustic emission.